Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 10,856 matching trials from the live ClinicalTrials.gov search.

Filters: Columbus, Ohio Clear all

Conditions: Labor and Delivery
Interventions: Epidural needle, Catheter Administration, Standard of Care Epidural Administration; Procedure
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 89 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Daytrana; Drug
Lead sponsor: Noven Therapeutics; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 29
States / cities: Scottsdale, Arizona • Irvine, California • San Marcos, California + 26 more

Conditions: Gastroesophageal Reflux Disease, Hiatal Hernia
Interventions: TIF Transoral Fundoplication, Sham placebo procedure; Device · Other
Lead sponsor: EndoGastric Solutions; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 9
States / cities: Los Angeles, California • Englewood, Colorado • Chicago, Illinois + 5 more

Conditions: Lymphoma, Extranodal NK-T-Cell, EBV
Interventions: baltaleucel-T; Biological
Lead sponsor: Cell Medica Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 5
States / cities: Boston, Massachusetts • Rochester, Minnesota • Columbus, Ohio + 1 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Not listed
Lead sponsor: Tempus AI; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 31
States / cities: Duarte, California • Los Angeles, California • Palo Alto, California + 25 more

Conditions: Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasm, Polycythemia Vera, Secondary Acute Myeloid Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib; Procedure · Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 3
States / cities: Columbus, Ohio • Portland, Oregon • Dallas, Texas

Conditions: Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Interventions: belinostat, carboplatin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 81
States / cities: Hartford, Connecticut • New Britain, Connecticut • Lewes, Delaware + 53 more

Conditions: Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions: behavioral dietary intervention, exercise intervention, behavioral activity counseling, telephone based counseling, quality-of-life assessment, questionnaire administration; Behavioral · Other · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Stroke, Patent Foramen Ovale, PFO
Interventions: Investigational PFO Closure Device, Standard of Care PFO Closure Device; Device
Lead sponsor: Occlutech International AB; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 27
States / cities: Phoenix, Arizona • Stanford, California • Thousand Oaks, California + 20 more

Conditions: Neuropathy Ulnar
Interventions: Simple decompression, Subcutaneous anterior transposition; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 10
States / cities: Atlanta, Georgia • Louisville, Kentucky • Baltimore, Maryland + 6 more

Conditions: Thoracoabdominal Aortic Aneurysm
Interventions: GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis; Device
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: 19 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 42
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 34 more

Conditions: Prostate Cancer
Interventions: GnRH agonist, Anti-androgen, TAK-700, Radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 165
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 136 more

Conditions: PostTraumatic Stress Disorder, Traumatic Brain Injury, Postconcussive Symptoms
Interventions: Active MeRT Treatment, Sham MeRT Treatment; Device
Lead sponsor: Wave Neuroscience; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 8
States / cities: Costa Mesa, California • Long Beach, California • San Diego, California + 5 more

Conditions: HIV Infections
Interventions: Lamivudine, Stavudine, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 31
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 21 more

Conditions: Autism
Interventions: RG1068 (Synthetic Human Secretin); Drug
Lead sponsor: Repligen Corporation; Industry
Eligibility: 32 Months to 59 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 15
States / cities: Phoenix, Arizona • Los Angeles, California • Oakland, California + 12 more

Conditions: Breast Cancer
Interventions: Trastuzumab, PF03512676, Correlative Studies; Drug · Other
Lead sponsor: Bhuvaneswari Ramaswamy; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Alzheimer Disease
Interventions: Rivastigmine 5 cm^2, Rivastigmine 10 cm^2, Rivastigmine 15 cm^2, Placebo to 15 cm^2 patch, Placebo to 10 cm^2 patch; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 1,584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 65
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 61 more

Conditions: Depressive Disorder, Major, Anhedonia
Interventions: Aticaprant, Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 51
States / cities: Birmingham, Alabama • Lafayette, California • Orange, California + 40 more

Conditions: Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions: Biospecimen Collection, Drug Withdrawn, Quality-of-Life Assessment, Questionnaire Administration, Tyrosine Kinase Inhibitor; Procedure · Other · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 25 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 157
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 123 more

Conditions: Duchenne Muscular Dystrophy
Interventions: delandistrogene moxeparvovec, placebo; Genetic
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 4 Years to 7 Years · Male only
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 23
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 20 more

Conditions: Hematologic Malignancies
Interventions: ProHema-CB, Untreated CB; Biological
Lead sponsor: Fate Therapeutics; Industry
Eligibility: 15 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 11
States / cities: Duarte, California • Atlanta, Georgia • Maywood, Illinois + 6 more

Conditions: Atrial Septal Defect
Interventions: GORE® CARDIOFORM ASD Occluder; Device
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: Not listed
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 17 more

Conditions: HIV Infections
Interventions: Saquinavir, Zalcitabine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 41
States / cities: Harbor City, California • La Jolla, California • Los Angeles, California + 27 more

Conditions: Ulcerative Colitis (UC)
Interventions: risankizumab IV, placebo for risankizumab, risankizumab SC; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 1,558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 82
States / cities: Coronado, California • Irvine, California • La Jolla, California + 63 more

Search by objective public record fields.

Epidural Loading: High Volume, Low Concentration

Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA

Randomized EsophyX Versus Sham / Placebo Controlled TIF Trial: The RESPECT Study

Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin

Intensive Diet and Exercise or Standard of Care in Improving Physical Function and Quality of Life in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy

Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

Clinical Trial for Surgery of the Ulnar Nerve (SUN) at the Elbow

Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Clinical Trial to Evaluate the Safety and Efficacy of MeRT Treatment in Post-Traumatic Stress Disorder

Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine

Synthetic Human Secretin in Children With Autism

Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline

A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.

Safety and Efficacy Study of Transcatheter Closure of Ostium Secundum ASDs

A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take Zidovudine

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis